الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 222 |  |  |
| | | from | 222 | | |
Abstract
Aim of the study Our current study aimed to demonstrate the anti-cancer effect by 3-BP to assess the cause that could induce cell death against mice carrying EAC. A study was conducted to compare bromopyruvate and different doses of other drugs such as hydroxychloroquine and Cisplatin. Search Plan: This study contained 100 Swiss white mice, which were divided into 10 groups as follows: 1- The first group: (10 mice) a naive control group that was injected with 0.9% salt solution. 2- The second group (10 mice) a positive control group that was injected into the abdomen with Irish cells at a concentration of 0.5 × 10 ^ 6. 3- The third group (10 mice) were injected Ip. in the peritoneum with BP of two weeks at a successful dose of 10 mg / kg. 4- The fourth group (10 mice) were injected Ip in the Ehrlich cell at a concentration of 0.5 * 10 ^ 6 and were treated through the peritoneal membrane with BP for two weeks at a good dose of (10 mg /kg). 5- 5th group collection of (10 mice) were injected Ip. only with hydroxychloroquine for two weeks at a dosage of 60 (mg / kg) 6- Sixth group collection of (10mice) were injected Ip. of the Ehrlich cells at a concentration of 0.5 * 10 ^ 6 and were treated during the peritoneal membrane with hydroxychloroquine for two weeks at a dosage good of (60 mg/ kg). 7- Seventh group collection of (10 mice) were injected Ip. with hydroxychloroquine 60 mg / kg and BP for two weeks at a good dosage of (10 mg / kg). 8- The eighth group collection of (10 mice) were injected IP. of EAC at a concentration of 0.5 * 10 ^ 6 and were treated during the peritoneal membrane with BP and hydroxychloroquine for two weeks at a good dosage of (10 mg / kg). 9- The ninth group collection of (10 mice) were injected with Cisplatin for two weeks at a good dosage of (40 mg /kg). 10- The ten group collection of (10 mice) were injected IP. in the Ehrlich cell at a concentration of 0.5 * 10 ^ 6 and were treated during the peritoneal membrane with Cisplatin for two weeks at a good dosage of 40 mg / kg. At the end of the experiment, it was: 1- Numeral types of tumor cells and live and non-living cells of mice, which in turn determine neoplastic disease and the extent of improvement over the course of the experiment. 2- Determination of Liver parameters, Oxidative parameters hexokinase activity, beclin1. Results 1- The rate of change in weight: There was an increase in the weight of statistically significant weight in clusters of mice that were inoculated with a prescribed amount of 10 mg per kilogram of bromopyruvate + 60 mg per kilogram of hydroxychloroquine for a period of two weeks for hydroxychloroquine by a quantity of 60 milligram /kg for bromopyruvate in a dosage of 10 milligram /kg In comparison, a successful dosage of (40 mg / kg) of Cisplatin. 2- The effect on relative liver weight: Obviously, The results also exhibited a decrease in liver weight that the treatment group injected with a dose of 10 mg per kilogram of bromopyruvate + 60 mg per kilogram of hydroxychloroquine designed for two weeks compared to a dose of (40 mg/kg) of Cisplatin for hydroxychloroquine 60mg/kg For bromopyruvate 10 mg /kg. The effect of bromopyruvate to reduce the number of cancer cells: The results also showed that the group treated with the two doses together showed a decrease in number of live and dead cancer cells more than bromopyruvate in a dosage of 10 milligram /kg more than hydroxychloroquine more than Cisplatin. The effect of bromopyruvate on enzymes and some antioxidant defenses for mice: The results showed that treatment with bromopyruvate has a role in influencing the activity of some liver enzymes such as: Liver parameters: where an improvement was recorded in the activity of some measured enzymes compared to its activity in the liver of infected and untreated mice, which resulted in a tumor carrying an rise decrease in the activity of liver enzymes in the group treated with bromopyruvate and hydroxychloroquine together more than bromopyruvate more than hydroxychloroquine more than Cisplatin. But in total protein showed increase in hydroxychloroquine than cisplatin than bromopyruvate. Results also revealed that the group inoculated with bromopyruvate showed reduction in B.urea and B.Creatinine less in bromopyruvate and hydroxychloroquine together than bromopyruvate than Cisplatin , hydroxychloroquine . Oxidative parameters: The results also showed that the group treated with bromopyruvate showed an increase of CAT and GST, more in bromopyruvate and hydroxychloroquine together than bromopyruvate more than hydroxychloroquine than Cisplatin. The results also showed that the group showed a deficiency of MDA in hydroxychloroquine and bromopyruvate together than bromopyruvate than hydroxychloroquine than cisplatin. The results also showed total thiol more in bromopyruvate and hydroxychloroquine together than Cisplatin than bromopyruvate than hydroxychloroquine. The results also showed that the group showed a more TAC deficiency with Cisplatin than hydroxychloroquine. Than bromopyruvate than in bromopyruvate and hydroxychloroquine together . HCQ inhibits autophagy of EAC cells we additional achieved flow cytometry analysis of the autophagic marker (fluorescence intensity of autophagosome marker)the treatment of HCQ significantly inhibited cellular protective autophagy of EAC cells as compared with the EAC group. Remarkably, a combination of 3‐BP and HCQ has a good effect on autophagy of cancer cells .These results are dependable with the improved antitumor effect of both drugs on EAC cells and cell death. Besides, this explains why HCQ treatment (EAC + HCQ) significantly drops live tumor cells and not total cell count. Monitor hexokinase activity: Enzymatic activity was calculated by the colorimetric assay (OD450 nm) to measure the amount of NADH generated per min at (pH 8) at RT. The sample test was performed against the NADH standard curve. We determined the activity of HK2 in the experimental group. 3‐BP action expressively reduced the action of HK2 in tumor cells as compared with the EAC group (GP2). Notably, CIS treatment repressed HK2 activity as previously reported by our group.